Rhythm Pharmaceuticals downgraded by Oppenheimer
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer downgraded Rhythm Pharmaceuticals from Outperform to Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/19/2026 | $478.00 | Outperform | RBC Capital Mkts |
| 11/25/2025 | $136.00 | Buy | Citigroup |
| 11/5/2025 | Outperform → Perform | Oppenheimer | |
| 7/14/2025 | $130.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 7/10/2025 | $97.00 | Buy | Goldman |
| 7/7/2025 | $88.00 | Outperform | Leerink Partners |
| 4/7/2025 | $63.00 | Neutral → Buy | BofA Securities |
| 3/5/2025 | $78.00 | Buy | Stifel |
RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00
Citigroup initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $136.00
Oppenheimer downgraded Rhythm Pharmaceuticals from Outperform to Perform
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago. Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine, will present results from an ongoing Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), evaluating higher doses and longer treatment duratio
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). "Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria," was published in the peer-reviewed American Journal of Medical Genetics. This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of int
BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at two upcoming conferences. Hunter Smith will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026 at 12:50 p.m. ET; andDavid Meeker will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday,
DEFA14A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
S-8 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago. Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine, will present results from an ongoing Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), evaluating higher doses and longer treatment duratio
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. "We are thrilled to welcome Kim to our Board of Directors," said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. "Kim brings decades of leadership experience across biotechnology, diagnostics and commercial innovation, with a proven track record
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience
SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
-- IMCIVREE® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- First quarter 2026 net product revenue from global sales of IMCIVREE of $60.1 million ---- IMCIVREE granted Marketing Authorization by European Commission for the treatment of obesity and control of hunger in patients with acquired hypothalamic obesity -- -- Japanese regulatory review of New Drug Application for setmelanotide to treat acquired hypothalamic obesity underway -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharma
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Tuesday, May 5, 2026 to report its first quarter 2026 financial results and provide a corporate update. Also today, Rhythm announced that Hunter Smith, Chief Financial Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:00 a.m. ET. Live webcasts of both the financial results conference call and the
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity -- -- Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] -- -- Company to host conference call today at 7:00 p.m. ET -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceu